Welcome to Ophthalmogy


in

The United States branded ophthalmic pharmaceuticals markets for age-related macular degeneration (AMD), chronic dry eye, ocular allergies, and ocular NSAIDs (for post-cataract and refractive surgery inflammation and pain) represent key markets with significant unmet medical needs, primarily among the growing aging population. These unmet needs are related to both medication efficacies in the ability to restore vision and stop serious sight-threatening conditions as well as in quality of life parameters, which have a significant economic impact.

 With a top-heavy age distribution, exponentially growing healthcare costs, and many new therapeutics expected to hit the market in the next several years, the U.S. Ophthalmic Pharmaceuticals market is expected to grow from $1,261.0 million in 2005 to $5,019.0 million by 2012.